TY  - JOUR
AU  - Lezaić, Višnja
AU  - Petković, Nenad
AU  - Marić, Ivko
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Simić-Ogrizović, Sanja
AU  - Pejović, Vesna
AU  - Đukanović, Ljubica
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1882
AB  - Background: Balkan endemic nephropathy (BEN) hemodialysis patients require a higher dose of recombinant human erythropoietin for maintaining target hemoglobin level than patients with other kidney diseases. Objectives: Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases (non-BEN). Methods: Recombinant human erythropoietin (75U/kg) was administered subcutaneously to 10 BEN and 14 non-BEN hemodialysis patients. The predose plasma level of erythropoietin (Epo) was subtracted from all postdose levels. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software (Thermo Scientific, ver.5.0). Results: Although basal plasma Epo concentration was similar in BEN (20.1 +/- 10.3U/L) and non-BEN (15.1 +/- 8.1U/L; p=.1964) patients, there were significant differences between the groups for elimination rate constant (0.016 +/- 0.006 vs 0.026 +/- 0.011 hr(-1); p=.020) and elimination half-life (50.24 +/- 19.12 vs 33.79 +/- 18.91 hr, p=.048). These differences remained significant after adjustment for patient characteristics (age, sex, hennodialysis duration, ferritin, PTH and ACEI use). No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment. Conclusion: Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. This finding needs to be confirmed in a well-controlled study with a larger sample size.
PB  - Soc Espanola Nefrologia Dr Rafael Matesanz, Madrid
T2  - Nefrologia
T1  - The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients
VL  - 33
IS  - 4
SP  - 478
EP  - 485
DO  - 10.3265/Nefrologia.pre2013.Apr.11800
ER  - 

@article{
author = "Lezaić, Višnja and Petković, Nenad and Marić, Ivko and Miljković, Branislava and Vučićević, Katarina and Simić-Ogrizović, Sanja and Pejović, Vesna and Đukanović, Ljubica",
year = "2013",
abstract = "Background: Balkan endemic nephropathy (BEN) hemodialysis patients require a higher dose of recombinant human erythropoietin for maintaining target hemoglobin level than patients with other kidney diseases. Objectives: Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases (non-BEN). Methods: Recombinant human erythropoietin (75U/kg) was administered subcutaneously to 10 BEN and 14 non-BEN hemodialysis patients. The predose plasma level of erythropoietin (Epo) was subtracted from all postdose levels. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software (Thermo Scientific, ver.5.0). Results: Although basal plasma Epo concentration was similar in BEN (20.1 +/- 10.3U/L) and non-BEN (15.1 +/- 8.1U/L; p=.1964) patients, there were significant differences between the groups for elimination rate constant (0.016 +/- 0.006 vs 0.026 +/- 0.011 hr(-1); p=.020) and elimination half-life (50.24 +/- 19.12 vs 33.79 +/- 18.91 hr, p=.048). These differences remained significant after adjustment for patient characteristics (age, sex, hennodialysis duration, ferritin, PTH and ACEI use). No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment. Conclusion: Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. This finding needs to be confirmed in a well-controlled study with a larger sample size.",
publisher = "Soc Espanola Nefrologia Dr Rafael Matesanz, Madrid",
journal = "Nefrologia",
title = "The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients",
volume = "33",
number = "4",
pages = "478-485",
doi = "10.3265/Nefrologia.pre2013.Apr.11800"
}

Lezaić, V., Petković, N., Marić, I., Miljković, B., Vučićević, K., Simić-Ogrizović, S., Pejović, V.,& Đukanović, L.. (2013). The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients. in Nefrologia
Soc Espanola Nefrologia Dr Rafael Matesanz, Madrid., 33(4), 478-485.
https://doi.org/10.3265/Nefrologia.pre2013.Apr.11800

Lezaić V, Petković N, Marić I, Miljković B, Vučićević K, Simić-Ogrizović S, Pejović V, Đukanović L. The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients. in Nefrologia. 2013;33(4):478-485.
doi:10.3265/Nefrologia.pre2013.Apr.11800 .

Lezaić, Višnja, Petković, Nenad, Marić, Ivko, Miljković, Branislava, Vučićević, Katarina, Simić-Ogrizović, Sanja, Pejović, Vesna, Đukanović, Ljubica, "The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients" in Nefrologia, 33, no. 4 (2013):478-485,
https://doi.org/10.3265/Nefrologia.pre2013.Apr.11800 . .